¸¸¼º ÄáÆϺ´ ȯÀÚ¿¡¼ °íÇ÷¾ÐÀÇ Áø´Ü ±âÁØ Update: 2017 ACC/AHA °íÇ÷¾Ð °¡À̵å¶óÀÎÀÇ Àû¿ë
Updated Guideline for Diagnosis of Hypertension in Chronic Kidney Disease Patients: Based on 2017 ACC/AHA Hypertension Guideline
´ëÇѳ»°úÇÐȸÁö 2019³â 94±Ç 3È£ p.263 ~ p.267
ÃÖÈ«»ó(Choi Hong Sang) - Àü³²´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Hypertension affects the majority of patients with chronic kidney disease (CKD) and increases the risk of cardiovascular disease, end-stage renal disease and mortality. Previously, many hypertension guidelines have suggested blood pressure targets in patients with CKD. Recently, the American College of Cardiology/American Heart Association 2017 Guideline for Hypertension suggests a new definition for hypertension and therapeutic targets, which were equally applicated to patients with CKD. These changes reflect the results of the Systolic Blood Pressure Intervention Trial (SPRINT) study, but the renal outcome of intensive blood pressure control was not good. Furthermore, the majority of hypertension guidelines including those of the Korean Society of Hypertension and the European Society of Hypertension have retained the traditional definition. Herein, we intend to analyze in detail the effect of intensive blood pressure control on kidney through the post-hoc analyses of the SPRINT study.
Å°¿öµå
Hypertension, Chronic kidney disease, Guideline
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
º» Review artilce Àº °íÇ÷¾Ð ÁýÁß Ä¡·á±º¿¡¼ Ç¥ÁØ Ä¡·á±ºº¸´Ù ±Þ¼º½Å¼Õ»óÀ̳ª »õ·Î¿î ¸¸¼º ÄáÆϺ´°ú °°Àº ½ÅÀå »ç°ÇÀÌ ¸¹ÀÌ ¹ß»ýÇÏ¿´°í ±âÀú ¸¸¼º ÄáÆϺ´ ȯÀÚ¿¡¼µµ Åë°èÀûÀ¸·Î À¯ÀÇÇÑ À¯ÀÍÇÔÀ» Áõ¸íÇÏÁö ¸øÇÏ¿´Áö¸¸, ½Å¼Õ»óÀÌ ºñ±³Àû °æÇÏ°í °¡¿ªÀûÀ̸ç Ç÷¿ªÇÐÀû º¯È¿¡ ÀÇÇÑ ºÎºÐÀÌ ¸¹´Ù°í º¼ ¼ö ÀÖÀ¸¸ç ȯÀÚÀÇ »ç¸ÁÀ» °¨¼Ò½Ãų ¼ö ÀÖ´Â ÀÌÁ¡ÀÌ ÀÖ´Ù°í º¸°íÇÔ